Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, is the editor-in-chief of ASH Clinical News, serves as the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute, and is an associate professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, both in Cleveland, Ohio.
Articles
Future of Myelofibrosis Treatments
December 22nd 2023Aaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.
Approaches to Switching Therapies for Patients With MF
December 22nd 2023When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.
Risk Stratification of Patients With MF
December 21st 2023Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.
Moving Beyond JAK Inhibition for the Treatment of Myelofibrosis
October 18th 2023Aaron T. Gerds, MD, MS, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.
